Billiontoone (NASDAQ:BLLN) SVP Bosch John Roderick Ten Sells 1,416 Shares

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,416 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $120.00, for a total transaction of $169,920.00. Following the completion of the sale, the senior vice president directly owned 33,552 shares in the company, valued at approximately $4,026,240. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The shares were sold at an average price of $101.47, for a total transaction of $287,363.04.

Billiontoone Price Performance

NASDAQ BLLN opened at $122.33 on Thursday. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The stock has a market cap of $5.63 billion and a price-to-earnings ratio of 222.42. The company has a 50-day moving average price of $94.91 and a two-hundred day moving average price of $87.56.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. The business’s quarterly revenue was up 83.8% on a year-over-year basis. During the same period last year, the firm posted ($0.39) EPS. Analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Investors Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently modified their holdings of BLLN. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN acquired a new position in Billiontoone during the fourth quarter valued at $76,000. Smartleaf Asset Management LLC acquired a new position in Billiontoone during the fourth quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Billiontoone in the 4th quarter worth about $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone during the 4th quarter worth about $201,000.

Analyst Ratings Changes

Several research firms have recently issued reports on BLLN. JPMorgan Chase & Co. increased their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wells Fargo & Company cut their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Guggenheim began coverage on shares of Billiontoone in a research note on Monday. They set a “buy” rating and a $125.00 target price on the stock. Finally, BTIG Research dropped their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.